83
Participants
Start Date
December 16, 2005
Primary Completion Date
October 18, 2018
Study Completion Date
April 24, 2026
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Temozolomide
Given orally
Vorinostat
Given orally
Memorial Sloan Kettering Cancer Center, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
University of Pennsylvania/Abramson Cancer Center, Philadelphia
National Cancer Institute Neuro-Oncology Branch, Bethesda
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Wake Forest University Health Sciences, Winston-Salem
Duke University Medical Center, Durham
Emory University Hospital/Winship Cancer Institute, Atlanta
Moffitt Cancer Center, Tampa
University of Alabama at Birmingham Cancer Center, Birmingham
Cleveland Clinic Foundation, Cleveland
Henry Ford Hospital, Detroit
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
M D Anderson Cancer Center, Houston
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
UCSF Medical Center-Mount Zion, San Francisco
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH